Notwithstanding promising clinical data, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing significant difficulty from managed care entities. The insurers are often erecting obstacles to coverage, like steep price criteria and approval processes that hinder patient access. Market suggest t… Read More